Targeted Plasmalogen Supplementation: Effects on Blood Plasmalogens, Oxidative Stress Biomarkers, Cognition, and Mobility in Cognitively Impaired Persons

Dayan B. Goodenowe1*, Jonathan Haroon2, Mitchel A. Kling3,4,5, Margaret Zielinski2, Kennedy Mahdavi2, Barshen Habelhah2, Leah Shtilkind1 and Sheldon Jordan2

1Prodrome Services USA LLC, Temecula, CA, United States, 2The Regenesis Project, Santa Monica, CA, United States, 3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, 4Crescenz VA Medical Center, Philadelphia, PA, United States, 5New Jersey Institute for Successful Aging, Department of Geriatrics and Gerontology, Rowan School of Osteopathic Medicine, Stratford, NJ, United States

Plasmalogens are a specific type of glycerophospholipid found in especially high levels in neuronal membranes. Decreased blood and brain levels of docosahexaenoic acid (DHA) containing plasmalogens are associated with decreased cognition and neuromuscular function in humans. Administration of 1-O-alkyl-2-acylglycerol (AAG) plasmalogen precursors containing DHA at the sn-2 position dose-dependently increase blood DHA plasmalogens and are neuroprotective in animal models of neurodegeneration at doses between 10 and 50 mg/kg. We conducted an investigational clinical trial in 22 cognitively impaired persons to evaluate the effects of an escalating oral dosing regimen of DHA-AAG from 900 to 3,600 mg/day over a 4-month period on blood serum plasmalogen and non-plasmalogen phospholipids and oxidative stress biomarkers. Safety, tolerability and therapeutic effects on cognition and mobility were also evaluated. DHA plasmalogen levels increased with increasing dose and remained significantly elevated at all treatment doses and durations. DHA plasmalogen levels were positively associated with catalase activity and negatively associated with malondialdehyde (MDA) levels. DHA-AAG supplementation normalized catalase activity in persons with low baseline catalase activity, normalized MDA levels in persons with high baseline MDA levels, and normalized superoxide dismutase activity in persons with high baseline SOD activity. Cognition improved in nine participants, was unchanged in nine, and declined in four. Mobility improved in twelve, was unchanged in five and declined in four participants. Changes in cognition and mobility were statistically significant versus a random outcome. Baseline DHA-plasmalogen levels were not predictive of clinical response. DHA-AAG was well tolerated at all dosages and no adverse reactions were observed.

Keywords: plasmalogen, sarcopenia, dementia, oxidative stress, catalase, malondiadehyde, superoxide dismutase, alkylglycerol (AKG)
INTRODUCTION

A 2021 survey of 1,221 adults in the US revealed that cognitive decline and the loss of mobility were the two most feared health outcomes (Author Anonymous, 2021). The prevalence of dementia in persons with sarcopenia is approximately three times higher than in persons without sarcopenia (Pacifico et al., 2020) and reduced muscle function is associated with increased risk of incident dementia and a faster rate of cognitive decline (Beeri et al., 2021). Reduced cognition and reduced mobility are comorbid. Reduced cognition and reduced mobility are also associated with plasmalogens deficiency. In humans, the association between low blood and brain plasmalogen levels and reduced cognition is robust and reproducible (Ginsberg et al., 1995; Ginsberg et al., 1998; Guan et al., 1999; Han et al., 2001; Han, 2005; Goodenowe et al., 2007; Wood et al., 2010; Wood et al., 2011a; Goodenowe and Senanayake, 2019; Senanayake and Goodenowe, 2019; Kling et al., 2020; Lim et al., 2020; Goodenowe, 2021). In animal models of plasmalogen deficiency, neuromuscular junction defects (Dorringer et al., 2017a; Dorringer et al., 2017b) have been reported and the selective knockout of oligodendrocyte peroxisomes cause white matter plasmalogen defects, morphology and symptomology similar to multiple sclerosis (Kassmann et al., 2007). These observations imply that impaired or insufficient plasmalogen related functions may represent a putative common link between dementia and sarcopenia.

A core component of human physiology is the compartmentalization of specific and distinct functions at both the intra- and intercellular level. The integrity and maintenance of function of these compartments are dependent upon efficient communication and transport of materials between compartments. This biochemical compartmentalization of function is dependent upon the physical and operational integrity of the biological membranes that separate cells from one another and divide intracellular space into various organelles and cytoplasm. These membranes are mostly comprised of glycerol phospholipids and cholesterol. The ability of cells and subcellular organelles to maintain optimal membrane functionality is dependent upon the cell’s ability to regulate its membrane composition. Membrane composition regulation, in turn, is dependent upon a complex interdependent mix of genetics, environment, and nutrition.

The backbone of most phospholipids is glycerol—a simple three carbon molecule with a single free alcohol on each carbon. The three carbons are commonly referred to as sn-1, -2, or -3. Glycerol phospholipids contain a polar phosphate-linked head group at sn-3. Phospho-ethanolamine or phospho-choline are the most abundant and ubiquitous phospholipid head groups in the human body. The sn-1 position is comprised of either a fatty alcohol (plasmalogen) or fatty acid (phosphatidyl). The sn-1 bond type and the type of fatty acid at sn-2 are the key determiners of the effect of membrane phospholipid composition on membrane structure and cellular function (Mankidy et al., 2010; Wood et al., 2011a). When alkylacylglycerols (AAG) are converted to ethanolamine plasmalogens (PL) the PL species retains the sn-2 fatty acid of the AAG. In vitro studies have shown that increasing membrane levels of DHA-plasmalogens using DHA-AAG dose-dependently increases the non-amyloidogenic processing of amyloid precursor protein (APP) via an upregulation of the alpha-secretase pathway resulting in an equally dose dependent increase in secreted APP-alpha and a dose-dependent decrease in Aβ1-42 (Wood et al., 2011a). In addition, increasing membrane DHA plasmalogen levels increases HDL-mediated cholesterol transport by dose-dependently increasing cholesterol esterification via acetyl-CoA acyltransferase (ACAT) and dose-dependently decreases the level of free cholesterol in membranes (Mankidy et al., 2010). DHA-AAG plasmalogen precursor also blocks the increase in Aβ1-42 caused by cholesterol loading (Wood et al., 2011a).

There has been an increasing interest in plasmalogens as a potential therapeutic agent for age-related cognitive decline and neurodegenerative conditions, given the growing understanding of their involvement in key cellular functions as well as the clinical trends observed when plasmalogens levels are depleted. In addition to supporting the structural integrity of membranes, plasmalogens are also involved in a variety of critically important cell functions: membrane fusion, ion transport, vesicle formation, cholesterol and amyloid regulation, and oxidation-reduction (Genser and Gross, 1994; Genser and Gross, 1995; Sindelar et al., 1999; Zoeller et al., 1999; Farooqui et al., 2000; Munn et al., 2003; Mankidy et al., 2010; Wood et al., 2011b; Wood et al., 2011c; Stables and Gilroy, 2011; Messias et al., 2018). In addition, recent research has shown that oral, DHA-enriched plasmalogen supplementation in mice increased hippocampal plasmalogen levels, improved learning and memory, and modulated various cell signaling pathways. In particular, research results suggested that the observed effect of oral plasmalogens on memory and learning were due, in part, to enhanced brain derived neurotrophic factor (BDNF) expression (Hossain et al., 2022). These observations are consistent with the detailed post-mortem examination of plasmalogen and phosphatidyl ethanolamine species, neuropathology and premortem cognition in human (Goodenowe and Senanayake, in press). Epidemiologically, it has been demonstrated that plasmalogen levels in the brain increase up to 30–40 years of age, and then significantly decrease by around 70 years of age (Rouser and Yamamoto, 1968; Goodenowe, 2021) and plasmalogen supplementation has been reported to improve cognition in humans (Fujino et al., 2017; Fujino et al., 2018).

Aging-related neurological and muscular degeneration lack accessible and effective therapeutic interventions. A possible treatment approach would involve a supplementation regimen of a plasmalogen precursor, such as the DHA-AAG plasmalogen precursor investigated in this study.

MATERIALS AND METHODS

Study Participants

Twenty-two persons diagnosed with cognitive impairment were enrolled. Eleven were male and eleven were female and their ages...
Cognitive impairment ranged from mild/questionable (n = 14), to mild dementia (n = 4), to moderate dementia (n = 4) according to the Clinical Dementia Rating Scale (CDR). No biomarker analyses were performed prior to enrollment and no pre-selection occurred. 29 persons were screened, four were excluded due to non-compliance, and three dropped out due to non-trial related reasons. All participants signed informed consent forms and the trial registration number was NCT04484454.

Study Materials
The DHA-AAG (Prodrome Sciences United States LLC) was used as a synthetic alkyl-acylglycerol comprised of C16 and C18 alkylglycerol backbone (chimyl and batyl alcohol) with DHA covalently bound to the sn-2 and sn-3 positions. The relative proportion of C16 and C18 plasmalogen backbone was 1:1 and the relative proportion of the fatty acids at sn-2 and sn-3 were >95% DHA, 2–5% docosapentaenoic acid (DPA) and <2% eicosapentaenoic acid (EPA). The DHA was purified from an algae source. The average density of the final product was 0.9 g/ml which corresponded to 900 mg of active product per ml. Product purity was >98%. A 1-month supply of DHA-AAG was provided to participants after each visit. Participants were instructed to take DHA-AAG each morning at the following dosages: 1.0 ml/day (Month 1, M1); 2.0 ml/day (Months 2 + 3, M2, M3); 4.0 ml/day (Month 4, M4); 0 mg/day (Month 5, M5).

Clinical Assessments
Cognition and mobility assessments were administered at baseline and the end of each month of the study. The primary outcome for cognitive status was change in Clinical Dementia Rating level (CDR) derived using the Quick Dementia Rating System (QDRS). The QDRS is a 10-item questionnaire completed by an informed third party to the participant (caregiver, spouse, etc.). Scores range from 0 to 30 with higher scores representing greater cognitive impairment in a corresponding CDR level. The CDR rates cognitive function in six categories (memory, orientation, judgment and problem solving, and performance in community affairs, home and hobbies, and personal care). A CDR level of 0 indicates no dementia; CDR 0.5 represents MCI or very mild dementia; CDR 1, 2, or three corresponds to mild, moderate, or severe dementia respectively (Galvin, 2015).

The primary mobility outcome was the 30-s Sit/Stand test. Participants were given 30 s to fully stand and sit for as many repetitions as possible within the time window. The Sit/Stand test has been found to be both reliable and valid in assessing the functional mobility in older adults, and has also been shown to be sensitive to change (McAllister and Palombo, 2020).

A clinically relevant change in cognition or mobility was defined as a change in CDR of one or more units or a change in two or more sit/stands, respectively. The monthly CDR and sit/stand performance of each participant were evaluated to determine the relative cognitive and mobility status of each participant at the end of months four and five relative to their baseline assessment. Each participant was rated as either exhibiting functional improvement, no change, or decline.

At the end of the study, each participant was asked to evaluate the treatment regimen using an 11-point Global Rating of Change scale from −5 to +5 in which the participant rates the overall change in their health. No change is rated as “0”, improved health from minor “+1” to significant “+5”, and reduced health from minor “−1” to significant “−5” (Kamper et al., 2009). The individual participant results are presented in Table 4.

Blood Serum Collection
Blood was drawn by trained nurses in an on-site surgical center. Venous blood was collected in a 10 ml redtop vacutainer tube and allowed to clot for 45–120 min. Serum was separated from the whole blood sample via centrifugation and stored at −80°C until processing.

Plasmalogen Extraction and Analysis
Serum samples were extracted using a modified version of the protocol described by Goodenowe et al. (Goodenowe et al., 2007). Briefly, 10 µL of serum was diluted with 50 µL of 0.1% formic acid and subjected to extraction three times with 1.0 ml of acidified ethyl acetate (98.2 ethyl acetate: 0.1% formic acid). Extracts were directly injected into a Thermo Fisher Scientific LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific, MA, United States) in both positive and negative ionization electrospray modes at a flow rate of 200 µL/min. Full scan mass spectral data were collected for masses of 150–1,200 amu at maximum resolution. A common pooled reference serum sample was prepared before the study and aliquots of this pooled serum were extracted with each batch of study samples and run on the mass spectrometer at the beginning, middle, and end of each run batch to monitor and correct for batch-to-batch variance throughout the study. Phospholipid species of interest were identified based upon their (M-H)− or (M) or (M + H)+ accurate masses (mass accuracy <1 ppm). Only accurate mass species represented by single Gaussian peaks subjected to baseline resolution from any surrounding mass peaks were included in the analyses. The intensity of each species was determined by averaging 20 contiguous scans.

Serological Analyses
Catalase activity capacity (ThermoFisher Scientific), superoxide dismutase activity capacity (Cayman Chemical Company), and malondialdehyde levels (Northwest Life Science Specialties) were measured according to the manufacturer’s specifications.

Statistical Analyses
Stata (version 14.2) was used for all statistical analyses.

RESULTS
Pharmacokinetic Evaluation of DHA-AAG on Serum Levels of Omega-3 and Omega-6 Containing Ethanolamine Phospholipids.
To evaluate the dose effects of DHA-AAG administration on serum ethanolamine phospholipid levels, four composite indices representative of the key serum omega-6 [linoleic acid (LA) and arachidonic acid (AA)] and omega-3 (DHA) phosphatidylethanolamine (PE) and ethanolamine plasmalogen...
Species were created (Table 1). From these four composite indices, three omega-3/6 ratio indices were created: DHA-PE/(LA + AA)-PE, DHA-PL/(LA + AA)-PL and DHA-PL/(LA + AA)-PE. These seven indices were then used to evaluate the absolute and relative effects of an escalating DHA-AAG dose on serum ethanolamine phospholipid levels (Figures 1A,B, Supplementary Table S1). The serum level of each index for each participant at all time points was normalized to the respective baseline group mean of that index.

Since DHA-AAG is comprised of a plasmalogen backbone with DHA covalently bound at sn-2 it is a direct precursor to DHA-PL; an indirect precursor to DHA-PE and (LA + AA)-PL; and is biochemically unrelated to (LA + AA)-PE. Figure 1A illustrates that the plasmalogen precursor DHA-AAG dose-dependently elevated both direct and indirect target species [DHA-PL, DHA-PE, and (LA + AA)-PL] and had no effect on the levels of the biochemically unrelated PE species index (LA + AA)-PE. DHA-AAG had a greater elevating effect on its direct target, DHA-PL than its indirect targets. The 1-month washout

### TABLE 1 | Ethanolamine phospholipid indices.

| Index Species Molecular formula [M-H]- | Species Molecular formula [M-H]- |
|----------------------------------------|------------------------------------|
| (LA + AA)-PE PtdEt 18:0/18:2 C 41H78NO8P 742.5392 | PE Omega-6 Index PtdEt 18:0/20:4 C 43H74NO8P 750.5130 |
| PE Omega-3 Index PtdEt 18:0/22:6 C 43H78NO8P 774.5443 | DHA-PE PtdEt 18:0/22:6 C 43H74NO8P 762.5079 |
| (LA + AA)-PL PlsEt 18:0/18:2 C 41H78NO7P 726.5443 | PE Omega-6 Index PlsEt 18:0/20:4 C 41H74NO7P 722.5130 |
| PL Omega-6 Index PlsEt 18:0/20:4 C 43H78NO7P 750.5443 | DHA-PL PlsEt 16:0/22:6 C 43H74NO7P 746.5130 |
| PL Omega-3 Index PlsEt 18:0/22:6 C 45H78NO7P 774.5443 | (LA + AA)-PE PtdEt 18:0/20:4 C 41H78NO7P 742.5392 |

**FIGURE 1 | (A)**-Serum levels of direct (DHA-PL), indirect (DHA-PE, (LA + AA)-PL), and non ((LA + AA)-PE) target phospholipid species. **(B)**-serum levels of selected phospholipid ratios. **(C)**-serum levels of DHA-PL in persons with high versus low baseline DHA-PL/(LA + AA)-PE levels. Values are means ± SEM. *, *p* < 0.05 versus baseline, student’s t-test (two-tailed).
period resulted in decreased levels of both the direct and indirect target species and no effect on the unrelated PE species.

To more precisely evaluate the effects of DHA-AAG on the levels of the direct, indirect, and unrelated ethanolamine phospholipid species, internal ratios of the omega-3 and omega-6 indices were evaluated in each subject over the course of the study as illustrated in Figure 1B. The relative ratio of the direct target DHA-PL to the unrelated (LA + AA)-PE was observed to exhibit the greatest elevation with dose and time. The relative ratio of the indirect DHA-PE to the unrelated (LA + AA)-PE exhibited the second greatest dose and time elevation and the relative ratio of the direct DHA-PL to the indirect (LA + AA)-PL exhibited the smallest dose and time effect. Figures 1A,B illustrate that DHA-AAG is converted to its direct and indirect target species in humans as predicted from animal studies on similar AAG plasmalogen precursors (Wood et al., 2011d).

Participants were not evaluated for DHA-PL levels prior to enrollment. To evaluate the effect of baseline DHA-PL levels on DHA-AAG pharmacokinetics, the participants were divided into either lower or upper halves based upon their baseline DHA-PL/DHA-AAG pharmacokinetics, the participants were divided into two enrollment groups. To evaluate the effect of baseline DHA-PL levels on each of the plasma indices, participants were grouped based upon their baseline DHA-PL or DHA-PL/(LA + AA)-PE (Figure 1C) or their DHA-PL/(LA + AA)-PE (Figure 1D) levels. As illustrated in Figures 1C,D, DHA-AAG elevated target species levels regardless of baseline DHA plasmalogen levels. However, participants with low baseline DHA-PL or DHA-PL/(LA + AA)-PE ratios experienced a greater relative improvement due to their low baseline levels and this relative improvement persisted even after the 1-month washout. Each participant’s baseline mean-normalized DHA-PL/(LA + AA)-PE ratio at baseline, end of month 4, and the maximum ratio observed is presented in Table 4.

Higher age was associated with lower levels of DHA-PL (LA + AA)-PL, higher levels of (LA + AA)-PE and lower levels of DHA-PL/(LA + AA)-PE and DHA-PE/(LA + AA)-PE (Supplementary Table S1). These data are consistent with previously published results in a large random population cohort (Wood et al., 2011a). Male sex was associated with lower levels of DHA-PE and (LA + AA)-PE (Supplementary Table S1). Lower levels of DHA-PE in males is consistent with previously published results in a large elderly cohort (Goodenowe and Senanayake, 2019).

Pharmacodynamic Evaluation of DHA-AAG on Serum Malondialdehyde, Catalase, and Superoxide Dismutase

The vinyl ether bond of the target ethanolamine plasmalogen species chemically reacts with reactive oxygen species to neutralize and prevent peroxidation of polyunsaturated fatty acids (Sindelar et al., 1999; Stadelmann-Ingrand et al., 2001). To determine if the DHA-PL elevating effect of DHA-AAG had a pharmacodynamic effect, levels of malondialdehyde (MDA), catalase (CAT), and superoxide dismutase (SOD) were measured at baseline, and at end of months 3, 4, and 5. MDA is a final end-product of lipid peroxidation of LA and AA. Penultimate to lipid peroxidation of all polyunsaturated fatty acids such as LA and AA is the insufficient neutralization of hydrogen peroxide. Excess hydrogen peroxide in the presence of superoxide anion can undergo conversion to the hydroxyl radical, which can then react with polyunsaturated fatty acids via a series of free radical reactions to form lipid peroxides. The superoxide anion is neutralized by SOD into molecular oxygen and hydrogen peroxide. Accordingly, SOD is the main producer of hydrogen peroxide. Catalase is a ubiquitous enzyme that neutralizes the hydrogen peroxide produced by SOD into water and molecular oxygen. Both SOD and CAT are potent inhibitors of lipid peroxidation (Gutteridge, 1984). SOD is a self-inducing enzyme in that the product of its activity (hydrogen peroxide) induces SOD synthesis (Yoo et al., 1999). In contrast, catalase is inactivated by hydrogen peroxide (Kokkaliari et al., 1992), and in an animal model of sarcopenia, increased superoxide anion is associated with increased SOD, increased hydrogen peroxide and decreased catalase (Sullivan-Gunn and Lewandowski, 2013).

Linear regression analysis of the seven phospholipid indices, MDA, CAT, and SOD is presented in Table 2. MDA is derived from the lipid peroxidation of LA or AA, so MDA levels are presumed to be influenced by both total LA + AA levels and overall peroxidation load. Interestingly (LA + AA)-PE, but not (LA + AA)-PL was positively associated with MDA levels. This observation indicates that the PL vinyl ether bond is likely protecting the PL bound AA from peroxidation in vivo as predicted by previous in vitro studies (Sindelar et al., 1999) thereby disassociating (LA + AA)-PL from MDA formation. Although both DHA-PL and DHA-PE levels were elevated by DHA-AAG treatment, only DHA-PL was observed to be negatively associated with MDA levels indicating that it is the PL vinyl ether bond, not DHA that is responsible for the negative association with MDA levels. All three omega-3/6 ratio indices were negatively associated with MDA levels. Catalase activity was negatively associated with MDA levels and DHA-PL was both positively associated with catalase activity and negatively associated with MDA.

Since it is unclear from the binary associations in Table 2 as to the dominance, independence, or relative contributions of the serological biomarkers to MDA and CAT levels, multivariate linear regression analysis was performed using multiple models (Table 3). This analysis showed that (LA + AA)-PE was the dominant predictor MDA levels. CAT had a strong negative association with MDA levels (Model 5), but this association was lost when PL species were included (Model 7). The increase in R-squared value when CAT was added to the PL model (Model 7 vs. 2) was minimal indicating that the effect of CAT on MDA levels was being caused by the effect of the PL species on CAT. This is clearly observed by comparing Model 9 vs. 14 wherein the PL species exhibited the strongest association with CAT (Model 9) which was minimally affected by the addition of MDA (Model 14). Collectively, these data indicate that the elevation of DHA-PL by DHA-AAG was independently associated with an increase in (LA + AA)-PL, CAT, and a decrease in MDA (Model 15).

To investigate potential ceiling or floor effects on MDA, CAT, and SOD, participants were grouped based upon their
baseline levels and the effect of DHA-AAG treatment evaluated in the lower and upper halves of each (Figure 2). This analysis revealed that DHA-AAG treatment normalized MDA in persons with high baseline MDA levels, SOD activity in persons with high baseline SOD activity, and CAT activity in persons with low baseline CAT activity.

**TABLE 2** | Relationship between key serological indices.

| Variable               | MDA (coef, p) | CAT (coef, p) | SOD (p) | PE (LA + AA) (Coef, p) | PE (DHA) (Coef, p) |
|------------------------|---------------|---------------|----------|------------------------|-------------------|
| (LA + AA)-PE           | 0.718         | 1.5e-07       | NS       | NS                     | -                 |
| DHA-PE                 | -             | -             | NS       | NS                     | -                 |
| DHA/(LA + AA)-PE       | -0.427        | 5.7e-04       | 0.596    | 4.3e-03                | NS                |
| (LA + AA)-PL           | -             | NS            | NS       | NS                     | 0.503             |
| DHA-PL                 | -0.233        | 3.3e-02       | 0.549    | 2.2e-03                | 2.4e-03           |
| DHA/(LA + AA)-PL       | -0.372        | 8.9e-04       | 0.736    | 6.1e-05                | -0.298            |
| PL Omega-3/PE Omega-6  | -0.349        | 6.4e-06       | 0.397    | 2.9e-03                | -                 |
| MDA                    | -             | -             | -0.474   | 7.9e-03                | NS                |
| CAT                    | -             | -             | NS       | -                      | -                 |

All variables were mean normalized and log10 transformed prior to linear regression analysis. Abbreviations: MDA = Malondialdehyde, CAT = Catalase, SOD = Superoxide Dismutase. For description of PE and PL species and indices see Table 1.

**TABLE 3** | Multivariate analyses of selected serological markers associated with catalase and malondialdehyde.

| Model | Outcome | Variables               | Coef   | p     | R-squared |
|-------|---------|-------------------------|--------|-------|-----------|
| 1     | MDA     | DHA-PE (LA + AA)-PE     | -0.225 | 5.4e-02 | 0.313     |
|       |         |                         | 0.846  | 3.8e-08 |           |
| 2     | MDA     | DHA-PL (LA + AA)-PL     | -0.368 | 2.1e-03 | 0.124     |
|       |         |                         | 0.380  | 1.1e-02 |           |
| 3     | MDA     | DHA-PL (LA + AA)-PE     | -0.146 | 1.3e-01 | 0.301     |
|       |         |                         | 0.685  | 5.6e-07 |           |
| 4     | MDA     | DHA-PL CAT              | -0.233 | 3.3e-02 | 0.053     |
|       |         |                         | -0.474 | 7.9e-03 | 0.081     |
| 5     | MDA     | DHA-PL CAT              | -0.156 | 1.6e-01 | 0.102     |
|       |         |                         | -0.141 | 3.6e-02 |           |
| 6     | MDA     | DHA-PL (LA + AA)-PL CAT | -0.290 | 2.5e-02 | 0.147     |
|       |         |                         | 0.316  | 4.1e-02 |           |
| 7     | MDA     | DHA-PE (LA + AA)-PE     | 0.577  | 1.0e-02 | 0.094     |
|       |         |                         | -0.634 | 2.0e-02 |           |
| 8     | CAT     | DHA-PE (LA + AA)-PE     | 0.577  | 1.0e-02 | 0.094     |
|       |         |                         | -0.634 | 2.0e-02 |           |
| 9     | CAT     | DHA-PL (LA + AA)-PL     | 0.776  | 8.3e-05 | 0.179     |
|       |         |                         | -0.639 | 8.4e-03 |           |
| 10    | CAT     | DHA-PL (LA + AA)-PE     | 0.525  | 3.9e-03 | 0.113     |
|       |         |                         | -0.187 | 4.3e-01 |           |
| 11    | CAT     | DHA-PL                  | 0.549  | 2.2e-03 | 0.106     |
| 12    | CAT     | MDA                     | -0.474 | 7.9e-03 | 0.081     |
| 13    | CAT     | DHA-PL MDA              | 0.463  | 9.7e-03 | 0.153     |
|       |         |                         | -0.368 | 3.6e-02 |           |
| 14    | CAT     | DHA-PL (LA + AA)-PL MDA | 0.680  | 8.9e-04 | 0.200     |
|       |         |                         | -0.540 | 3.0e-02 |           |
| 15    | CAT     | DHA-PL (LA + AA)-PL CAT MDA | 0.639 | 1.5e-07 | 0.378     |
|       |         |                         | 0.186  | 8.9e-04 |           |
|       |         |                         | -0.207 | 2.5e-02 |           |
| 16    | DHA-PL  | DHA-PE (LA + AA)-PE     | 0.807  | 1.2e-15 | 0.403     |
|       |         |                         | -0.716 | 7.0e-10 |           |

All variables were mean normalized and log10 transformed prior to linear regression analysis. Abbreviations: MDA = Malondialdehyde, CAT = Catalase, SOD = Superoxide Dismutase. For description of PE and PL species and indices see Table 1.
Clinical Evaluation of DHA-AAG on Cognition and Mobility

Of the 22 participants who completed the study, cognition improved in 9 (41%), declined in 4 (18%) and remained stable in 9 (41%) during the 4-months treatment period (Table 4). No relationship between baseline DHA-PL levels and response or lack of response was observed (5 in lower half and four in upper half). However, a higher proportion of persons with more severe baseline cognitive impairment improved than persons with mild cognitive impairment (3/4 subjects with baseline CDR of 2; 2/4 subjects with baseline CDR of 1, and 4/14 subjects with baseline CDR = 0.5). Mobility improved in 12 participants (55%), remained stable in 5 (23%) and declined in 4 (18%). Using a random non-response based upon the observed decline rate as the predictor, the observed response rates were significant for both cognition and mobility (Table 5). At the end of the trial each participant was asked to self-evaluate the overall effect of the DHA-AAG treatment using the Global Rating of Change scale (Kamper et al., 2009). Of the eighteen participants who completed the GRC, twelve reported that their health improved over the 4-month trial and six reported no change. No participant reported a negative change. The individual participant responses are included in Table 4.

DISCUSSION

This open-label investigational study evaluated the clinical and serological effects of an escalating dose of DHA-AAG (900 mg/day—3,600 mg/day) in cognitively impaired persons. Each dose was administered for at least 1 month and a 1-month washout at the end of the trial was used. Pharmacokinetic, pharmacodynamic, and clinical outcomes were monitored.

The key pharmacological observation was that the plasmalogen precursor DHA-AAG exhibited a dose-dependent and species-selective elevating effect on serum ethanolamine phospholipids. Specifically, DHA-containing PL species were preferentially elevated. Non-DHA containing PL species and DHA-containing PE species were also elevated, but to a lesser extent. Non-DHA PE species were unaffected by the DHA-AAG.
These observations are consistent with the previously proposed metabolic fate of AAG (Mankidy et al., 2010; Wood et al., 2011a; Wood et al., 2011d) and summarized in Figure 3. In brief, 1-O-alkyl, 2,3-diacylglycerols are metabolized by gut lipases to 1-O-alkyl, 2-acylglycerol which is absorbed into the bloodstream and then converted to 1-O-alkyl-2-acylglycerophosphoethanolamine which is then desaturated to the final vinyl ether ethanolamine plasmalogen in endoplasmic reticulum of the cells of the body. Since no peroxisome-specific biochemical steps are required to convert AAG plasmalogen precursors into vinyl ether plasmalogens, AAG plasmalogen precursors bypass the obligate rate-limiting peroxisomal enzymes necessary for endogenous plasmalogen biosynthesis.

Several key pharmacodynamic observations and interpretations were made. First, serum MDA levels exhibited a strong positive correlation with serum levels of AA and LA containing PE species, but serum levels of AA and LA containing PL species were not correlated with MDA levels. It is hypothesized that, consistent with in vitro observations (Sindelar et al., 1999), the sn-1 vinyl ether bond of plasmalogens protects the sn-2 AA and LA from peroxidation and thus blocks the formation of MDA from AA and LA containing PL species. A higher level of serum DHA-PL was associated with a lower MDA level independent of LA and AA PE levels indicating a direct anti-peroxidation effect of serum DHA-PL. Secondly, MDA was negatively and DHA-PL was positively associated with serum CAT capacity. Detailed multivariate statistical analyses revealed that the positive association between serum DHA-PL levels and CAT capacity was independent of the MDA lowering effect of DHA-PL which is suggestive of a more generalized improvement in peroxisomal function following DHA-AAG supplementation—perhaps due to reduced endogenous administration.

### TABLE 4 | Individual participant demographics and clinical responses.

| Id | Age | Sex | CDR (BL) | S/S (BL) | CDR (M4) | S/S (M4) | DHA-PL/(LA + AA)-PE (BL) | GRC (Max (month)) |
|----|-----|-----|----------|----------|----------|----------|--------------------------|-------------------|
| 16 | 78  | F   | 2        | 3        | 16       | 14       | 0.29                     | 0.90 (M3)         |
| 19 | 58  | F   | 2        | 1        | 11       | 16       | 0.88                     | 2.15 (M4)         |
| 1  | 81  | M   | 2        | 1        | 11       | 15       | 0.90                     | 1.65 (M4)         |
| 29 | 63  | F   | 2        | 0.5      | 30       | 34       | 1.26                     | 2.69 (M5)         |

Group 2 — Mild Dementia (CDR = 1)

| Id | Age | Sex | CDR (BL) | S/S (BL) | CDR (M4) | S/S (M4) | DHA-PL/(LA + AA)-PE (BL) | GRC (Max (month)) |
|----|-----|-----|----------|----------|----------|----------|--------------------------|-------------------|
| 12 | 75  | M   | 1        | 1        | 15       | 16       | 0.72                     | 3.03 (M4)         |
| 18 | 80  | M   | 1        | 1        | 11       | 16       | 0.69                     | 1.35 (M2)         |
| 8  | 84  | M   | 1        | 0.5      | 13       | 15       | 0.57                     | 0.74 (M3)         |
| 21 | 48  | M   | 1        | 0.5      | 14       | 14       | 1.04                     | 2.38 (M2)         |

Group 3 — Mild Cognitive Impairment (CDR = 0.5)

| Id | Age | Sex | CDR (BL) | S/S (BL) | CDR (M4) | S/S (M4) | DHA-PL/(LA + AA)-PE (BL) | GRC (Max (month)) |
|----|-----|-----|----------|----------|----------|----------|--------------------------|-------------------|
| 11 | 69  | F   | 0.5      | 2        | NA       | NA       | 1.03                     | 2.44 (M4)         |
| 24 | 66  | F   | 0.5      | 2        | 13       | 16       | 0.36                     | 1.96 (M4)         |
| 7  | 81  | F   | 0.5      | 1        | 15       | 16       | 0.87                     | 1.57 (M4)         |
| 3  | 74  | F   | 0.5      | 0.5      | 13       | 17       | 0.41                     | 1.33 (M4)         |
| 6  | 74  | M   | 0.5      | 0.5      | 12       | 14       | 0.91                     | 2.69 (M4)         |
| 10 | 81  | M   | 0.5      | 0.5      | 19       | 22       | 0.87                     | 1.71 (M2)         |
| 20 | 78  | M   | 0.5      | 0.5      | 11       | 8        | 0.44                     | 1.10 (M3)         |
| 22 | 63  | F   | 0.5      | 0.5      | 13       | 12       | 2.27                     | 4.04 (M3)         |
| 23 | 64  | F   | 0.5      | 0.5      | 10       | 12       | 0.40                     | 1.79 (M4)         |
| 28 | 67  | F   | 0.5      | 0.5      | 12       | 14       | 2.38                     | 3.94 (M4)         |
| 2  | 37  | M   | 0.5      | 0        | 13       | 14       | 0.79                     | 1.54 (M4)         |
| 14 | 59  | M   | 0.5      | 0        | 14       | 12       | 1.24                     | 2.92 (M4)         |
| 16 | 64  | M   | 0.5      | 0        | 21       | 22       | 1.33                     | 2.73 (M5)         |
| 17 | 77  | F   | 0.5      | 0        | 11       | 14       | 0.34                     | 1.16 (M3)         |

BL — baseline, M4 — Month 4, S/S — Sit/Stand, GRC — Global Rating of Change, NA — Not Available.

### TABLE 5 | Categorical treatment response summary.

| Clinical Observation | CDR (observed) | CDR (predicted) | Sit/Stand (observed) | Sit/Stand (predicted) |
|----------------------|----------------|-----------------|----------------------|----------------------|
| Improvement          | 9              | 4               | 12                   | 4                    |
| No Change            | 9              | 14              | 5                    | 13                   |
| Decline              | 4              | 4               | 4                    | 4                    |

Chi Squared p-value: 1.8e-02

Predicted responses were based upon an assumed random non-response rate based upon the observed decline rate for each outcome.
plasmalogen synthesis demand. Thirdly, the effect of DHA-AAG on SOD activity appeared more complicated and less clear. Since SOD is inducible as well as degradable, we looked at the effect of DHA-AAG administration on persons with high or low SOD. DHA-AAG normalized both groups of participants. Further investigation is needed to confirm this observation, however it is possible that persons with a robust SOD biosynthesis capacity exhibit elevated SOD in the presence of excess hydrogen peroxide, which is alleviated by DHA-AAG whereas persons with a weak SOD biosynthesis capacity exhibit decreased SOD, which is enhanced by DHA-AAG.

Due to the small investigational nature of the study, cognition, as measured by QDRS and sarcopenia, as measured by the sit-stand test were evaluated as preliminary indices of potential clinical benefit from DHA-AAG supplementation. Despite the small number of participants, a clear participant benefit was observed. Participants self-reported increased energy, clarity of thought, and fluidity of movement. Two-thirds of the participants reported an increase in their global rating of change evaluation and one-third reported no change. None reported a decline (Table 4). QDRS is an objective evaluation of a person (the trial participant) by a third-party witness with intimate knowledge of the daily activities of the person. According to such third person observation, 9 (41%) of the participants displayed significant cognitive improvement, nine remained stable and 4 declined. Participants with the most severe cognitive impairment at baseline were observed to preferentially benefit from the DHA-AAG therapy in that three of the four participants with moderate dementia (CDR = 2) exhibited clinically meaningful improvement and two of the four participants with mild dementia (CDR = 1) exhibited clinically meaningful improvement. Improved mobility, as measured by the sit-stand test was more generally observed. Only one participant exhibited a decline in both cognition and mobility, whereas five participants exhibited improvements in both cognition and mobility and ten exhibited improvements in either cognition or mobility.

**SUMMARY AND CONCLUSION**

The study has several obvious attributes and limitations. It was designed to investigate the pharmacokinetic and pharmacodynamic effects of an escalating oral dose of DHA-AAG. It was not designed to critically evaluate clinical response. The pharmacokinetic (dose dependent increase in serum levels of the target DHA-PL species) and pharmacodynamic (increased CAT activity and decreased MDA levels) are robust and consistent with previous research results in animal models and *in vitro* studies. The DHA-AAG was well tolerated at the doses and durations administered. The small number of participants (22), short duration (4-months), and the lack of a sufficient placebo control or cross-over design are obvious limitations as to the interpretation of the positive clinical effects on
cognition and mobility observed. Clinical response data should be interpreted with caution. However, it is clear that subsequent clinical trials designed to more critically evaluate the clinical utility of DHA-AAG in dementia and sarcopenia are warranted.

Impact Statement
The study presented is the first targeted plasmalogen precursor treatment evaluation in humans. Numerous epidemiological and post-mortem studies have described structure-specific associations between plasmalogen deficiencies and reduced cognition and mobility. Numerous preclinical studies have similarly described structure-specific biological activities of plasmalogens. An escalating dose of a DHA-specific plasmalogen precursor (DHA-AAG) was administered to cognitively impaired persons and the pharmacokinetic, pharmacodynamic, and clinical effects evaluated. A dose-dependent elevation in DHA-plasmalogen levels was observed. Oxidative stress biomarkers (malondialdehyde, catalase, superoxide dismutase) improved and this improvement was correlated with higher DHA-plasmalogen levels. A statistically significant improvement in cognition and mobility was observed. The research results establish that blood levels of structurally specific plasmalogen species can be preferentially targeted and modulated and that this is a therapeutically viable approach worthy of further investigation and optimization for the treatment of plasmalogen deficiency mediated diseases.

REFERENCES

Author Anonymous (2021). The Top 5 Most Feared Health Conditions in 2021. https://www.medicareadvantage.com/news/
Beeri, M. S., Leugrans, S. E., Delbono, O., Bennett, D. A., and Buchman, A. S. (2021). Sarcopenia Is Associated with Incident Alzheimer’s Dementia, Mild Cognitive Impairment, and Cognitive Decline. J. Am. Geriatr. Soc. 69, 1826–1835. doi:10.1111/jgs.17206
Dorninger, F., Forss-Petter, S., and Berger, J. (2017). From Peroxisomal Disorders to Alzheimer’s Disease: A 15 Year Crusade to Expose the Causative Factor in Alzheimer’s Disease Brain. J. lipid Res. 58, 2533–2538. doi:10.1194/jlr.P069935-JLR200
Galvin, J. E. (2013). The Quick Dementia Rating System (Qdrs): A Rapid Dementia Staging Tool. Alzheimer’s & Dementia. Diagn. Assess. & Dis. Monit. 1, 249–259. doi:10.1016/j.dadm.2015.03.003

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the Sterling IRB. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
DBG designed the DHA-AAG plasmalogen precursor and oversaw the manufacturing. DBG prepared the manuscript. DBG, MAK, and SJ designed the trial. LS oversaw analytical testing. SJ oversaw the execution of the clinical trial. JH, KM, MZ, and BH generated the clinical data.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2022.864842/full#supplementary-material

Ginsberg, L., Xuereb, J. H., and Gershfeld, N. L. (1998). Membrane Instability, Plasmalogen Content, and Alzheimer’s Disease. J. Neurochem. 70, 2533–2538. doi:10.1046/j.1471-4159.1998.70062533.x
Ginsberg, L., Rafique, S., Xuereb, J. H., Rapoport, S. I., and Gershfeld, N. L. (1995). Disease and Anatomic Specificity of Ethanolamine Plasmalogen Deficiency in Alzheimer’s Disease Brain. Brain Res. 698, 223–226. doi:10.1016/0006-8993(95)00931-F
Glaser, P. E., and Gross, R. W. (1994). Plasmalogen Deficiency: Rapid Membrane Fusion: A Stopped-Flow Kinetic Investigation Correlating the Propensity of a Major Plasma Membrane Constituent to Adopt an HII Phase with its Ability to Promote Membrane Fusion. Biochemistry 33, 5805–5812. doi:10.1021/bi00185019
Glaser, P. E., and Gross, R. W. (1995). Rapid Plasmalogen Deficiency-Selective Fusion of Membrane Bilayers Catalyzed by an Isomeric Subtype of Glyceraldehyde-3-Phosphate Dehydrogenase: Discrimination between Glycolytic and Fusogenic Roles of Individual Isomers. Biochemistry 34, 12193–12203. doi:10.1021/bi00038013
Goodenowe, D. B., and Senanayake, V. (2019). Relation of Serum Plasmalogens and APOE Genotype to Cognition and Dementia in Older Persons in a Cross-Sectional Study. Brain Sci. 9. doi:10.3390/brainsci9040092
Goodenowe, D. B., Mack, L. L., Liu, J., Xuereb, J. H., Rapoport, S. I., and Gershfeld, N. L. (2007). Peripheral Ethanolamine Plasmalogen Deficiency: A Logical Causative Factor in Alzheimer’s Disease and Dementia. J. lipid Res. 48, 2485–2498. doi:10.1194/jlr.P069833-JLR200
Goodenowe, D. (2021). Breaking Alzheimer’s- A 15 Year Crusade to Expose the Cause and Deliver the Cure. USA: Dayan Goodenowe.
Gutteridge, J. M. C. (1984). Lipid Peroxidation Initiated by Superoxide-dependent Hydroxyl Radicals Using Complexed Iron and Hydrogen Peroxide. FEBS Lett. 172, 245–249. doi:10.1016/0014-5793(84)81134-5

Frontiers in Cell and Developmental Biology | www.frontiersin.org 10 July 2022 | Volume 10 | Article 864842
Han, X., Holtzman, D. M., and McKeel, D. W., Jr. (2001). Plasmalogen Deficiency in Early Alzheimer’s Disease Subjects and in Animal Models: Molecular Characterization Using Electrospray Ionization Mass Spectrometry. J. Neurochem. 77, 1168–1180. doi:10.1046/j.1471-4159.2001.00332.x

Han, X. (2005). Lipid Alterations in the Earliest Clinically Recognizable Stage of Alzheimer’s Disease: Implication of the Role of Lipids in the Pathogenesis of Alzheimer’s Disease. Car 2, 65–77. doi:10.2174/1567205052772786

Hossain, M. S., Matwari, S., and Fujino, T. (2022). Plasmalogens, the Vinyl Ether-Linked Glycerophospholipids, Enhance Learning and Memory by Regulating Brain-Derived Neurotrophic Factor. Front. Cell. Dev. Biol. 10, 828282. doi:10.3389/fcell.2022.828282

Kammer, S. J., Maher, C. G., and Mackay, G. (2009). Global Rating of Change Scales: a Review of Strengths and Weaknesses and Considerations for Design. J. Man. Manip. Ther. 17, 163–170. doi:10.1179/jmt.2009.17.3.163

Kassmann, C. M., Lappe-Siecle, C., Baes, M., Brügger, B., Mildner, A., Werner, H. B., et al. (2007). Axonal Loss and Neuroinflammation Caused by Peroxisome-Deficient Oligodendrocytes. Nat. Genet. 39, 969–976. doi:10.1038/ng2070

Kling, M. A., Goodenowe, D. B., Senanayake, V., MahmoudianDehkhordi, S., Arnold, M., Massaro, T. J., et al. (2020). Circulating Ethanolamine Plasmalogen Indices in Alzheimer’s Disease: Relation to Diagnosis, Cognition, and CSF Tau. Alzheimer’s &amp; Dementia. 16, 1234–1247. doi:10.1002/alz.12110

Kokkaliari, M., Fawibe, O., Berry, H., and Baum, H. (1992). Serum Catalase as the Protective Agent against Inactivation of Alpha 1-protease Inhibitor by Hydrogen Peroxide; Comparison between Normal and Rheumatoid Sera. Biochim. Bio. 28, 191–227.

Lim, W. L. F., Huynh, K., Chatterjee, P., Martins, I., Jayawardana, K. S., Giles, C., et al. (2020). Relationships between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer’s Disease. Jad 76, 303–315. doi:10.3233/jad-191304

Mankidy, R., Abiabouna, P. W. M., Ha, H., Jayasinghe, D., Ritchie, S. A., Khan, M. A., et al. (2010). Membrane Plasmalogen Composition and Cellular Cholesterol Regulation: a Structure Activity Study. Lipids Health Dis. 9, 62. doi:10.1186/1476-511x-9-62

McAllister, L. S., and Palombo, K. M. (2020). Modified 30-Second Sit-To-Stand Test: Reliability and Validity in Older Adults Unable to Complete Traditional Sit-To-Stand Testing. J. Geriatr. Phys. Ther. 43, 153–158. doi:10.1519/jpt.0000000000000027

Messia, M. C. F., Mecatti, G. C., Priolli, D. G., and de Oliveira Carvalho, P. (2018). Plasmalogen Lipids: Functional Mechanism and Their Involvement in Gastrointestinal Cancer. Lipids Health Dis. 17, 41. doi:10.1186/s12944-018-0685-9

Munn, N. J., Arnio, E., Liu, D., Zoeller, R. A., and Liscum, L. (2003). Deficiency in Ethanolamine Plasmalogen Leads to Altered Cholesterol Transport. J. lipid Res. 44, 182–192. doi:10.1194/jlr.m200363-jl200

Pacini, C., Geerlings, M. A. J., Reijnierse, E. M., Phassouliotis, C., Lim, W. K., and Sarna, J. (2011). Oral Bioavailability of the Ether Lipid Plasmalogen Precursor, PPI-1011, in the Rabbit: A New Therapeutic Strategy for Alzheimer’s Disease. Lipids Health Dis. 10, 227. doi:10.1186/1476-511x-10-227

Wood, P. L., Smith, T., Pelzer, L., and Goodenowe, D. B. (2011). Targeted Metabolomic Analyses of Cellular Models of Pelizaeus-Merzbacher Disease Reveal Plasmalogens and Myo-Inositol Solute Carrier Dysfunction. Lipids Health Dis. 10, 102. doi:10.1186/1476-511x-10-102

Yoo, H. Y., Chang, M. S., and Rho, H. M. (1999). The Activation of the Rat Copper/ zinc Superoxide Dismutase Gene by Hydrogen Peroxide through the Hydrogen Peroxide-Responsive Element and by Paracetamol and Heat Shock through the Same Heat Shock Element. J. Biol. Chem. 274, 23887–23892. doi:10.1074/jbc.274.34.23887

Zeolzer, R. A., Lake, A. C., Nagan, N., Gaposchkin, D. P., Legner, M. A., and Lieberthal, W. (1999). Plasmalogens as Endogenous Antioxidants: Somatic Cell Mutants Reveal the Importance of the Vinyl Ether. Biochem. J. 338 (Pt 3), 769–776. doi:10.1042/bj3380769

Conflict of Interest: Author DBG was a shareholder and employee of Prodrome Sciences USA LLC. LS was employed by the company Prodrome Sciences United States LLC.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Goodenowe, Haroon, Kling, Zielinski, Mahdavi, Habelhah, Shitkind and Jordan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.